Klaria Interim Report Q1 2022

Summary of the Interim Report

First quarter of 2022

- Net sales amounted to 0.0 MSEK (0.0 MSEK)

- R&D costs for the period amounted to 17.1 MSEK (11.4 MSEK)

- Profit after tax amounted to -20.3 MSEK (-16.7 MSEK)

- Earnings per share for the quarter amounted to -0.37 SEK (0.32 SEK)

- Cash flow from operating activities amounted to -19.8 MSEK (17.1 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 23.0 MSEK (48.2 MSEK)

- Equity as of March 31 amounted to 72.1 MSEK (126.3 MSEK)

- Pursuant to the authorization granted by the Annual General Meeting on March 18, 2021, the Board decided on a directed share issue of a maximum of 5,750,000 shares with a subscription price of 4SEK per share, corresponding to a gross payment of no more than 23 MSEK before issue costs

- Klaria Pharmaceuticals signs agreement with FluiMed GmbH to develop Sirolimus Alginate Film for prevention of Organ Transplant Rejection